Loading live market data…

Axcella Health Inc.

NASDAQ:AXLA

$4.58 USD

$0 (0.0%)

Volume
6.78K
Average Volume
37.08K
Market Capitalization
$12.5M
P/E Ratio
-3.61
Dividend Yield
0.00%
Price Target
$60.00
Year High
$4.58
Year Low
$0.36
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.21

Industry, Sector & symbol

Stock Exchange NASDAQ
CEO Craig R. Jalbert CIRA
Industry Biotechnology
Sector Healthcare
Current Symbol AXLA
CUSIP 05454B204
CIK 0001633070
Web https://www.axcellahealth.com
Phone 857 320 2200
Currency USD
Employees 11
Country US

Liquidity

Debt-to-Equity Ratio 0.52
Payout Ratio 0.00
Current Ratio 1.21
Quick Ratio 1.21
Cash Ratio 1.21

Sales & Book Value

Annual Sales $-
Price / Sales 0.00
Cash Flow -1.09
Price / Cash Flow -0.18
Price / Book 70.41

Price Target and Rating

Average Stock Price Forecast $60.00
High Stock Price Forecast $60.00
Low Stock Price Forecast $60.00
Forecast Upside/Downside -92.37%
Consensus Rating N/A
Rating Score(0-5) 0
Research Coverage 10 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-1.27
Trailing P/E Ratio -3.61
PEG Ratio 0.07
P/E Growth 0.07
Net Income $-81.19M
Net Margin 0.00%
Pretax Margin 0.00%
Return on Equity -620.40%
Return on Assets -428.94%

Financials Score

AltmanZ Score -80.09
Piotroski Score 3.00
Working Capital -2.27M
Total Assets 9.28M
Ebit -45.64M
Market Cap 12.5M
Total Liabilities 11.54M

Poll Results

About Axcella Health Inc. (NASDAQ:AXLA) Stock

Axcella Health Inc. is a U.S.-based clinical-stage biotechnology firm focused on developing novel therapeutic compositions derived from endogenous metabolic modulators. These aim to address complex diseases and improve overall health. The company's primary drug candidates are AXA1665 and AXA1125. AXA1665 is currently undergoing Phase 2 clinical trials, where it is being evaluated for its potential to lower the risk of recurrent overt hepatic encephalopathy. Meanwhile, AXA1125 is progressing through multiple trials: a Phase 2b study targeting non-alcoholic steatohepatitis (NASH) treatment, and a Phase 2a study exploring its efficacy as a therapy for Long COVID patients. Founded in 2008, the entity initially operated as Newco LS16, Inc. before officially adopting the name Axcella Health Inc. ... in June 2016. Its operations are headquartered in Cambridge, Massachusetts.

Frequently Asked Questions

What is the current Axcella Health Inc. (AXLA) stock price?

Axcella Health Inc.(NASDAQ:AXLA) stock price is $4.58 in the last trading session. During the trading session, AXLA stock reached the peak price of $4.58 while $4.58 was the lowest point it dropped to. The percentage change in AXLA stock occurred in the recent session was 0.0% while the dollar amount for the price change in AXLA stock was $0.

AXLA's industry and sector of operation?

The NASDAQ listed AXLA is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of AXLA?

William R. Hinshaw Jr. | President, Chief Executive Officer & Director
Alison D. Schecter | President of Strategy & Operations
Paul Fehlner | Senior Vice President, Chief Legal Officer & Corporate Secretary
Craig R. Jalbert | President, Chief Executive Officer, Treasurer, Secretary, Financial and Accounting Officer & Director
Marie Washburn | Vice President of Finance & Corporate Controller

How many employees does AXLA have?

Number of AXLA employees currently stands at 11. AXLA operates from 840 Memorial Drive, Cambridge, MA 02139, US.

Link for AXLA official website?

Official Website of AXLA is: https://www.axcellahealth.com

How do I contact AXLA?

AXLA could be contacted at phone #857 320 2200 and can also be accessed through its website. AXLA operates from 840 Memorial Drive, Cambridge, MA 02139, US.

How many shares of AXLA are traded daily?

The average number of AXLA shares traded daily for last 3 months was 37.08K.

What is the market cap of AXLA currently?

The market value of AXLA currently stands at $12.5M with its latest stock price at $4.58